Trump administration pick for Health and Human Services department could cause rise in preventable disease, health expert ...

Scott Gottlieb, who served as commissioner of the Food and Drug Administration (FDA) during President-elect Trump’s first ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

The healthcare industry thrives due to novel drug pipeline discoveries, AI integration to streamline processes and technological advancements. So, investing in undervalued healthcare stocks with ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing ...